Akari Therapeutics (NASDAQ: AKTX)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-09-21 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-07-08 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Akari Therapeutics (NASDAQ: AKTX) through any online brokerage.
Other companies in Akari Therapeutics’s space includes: Opiant Pharma (NASDAQ:OPNT), Cocrystal Pharma (NASDAQ:COCP), SCYNEXIS (NASDAQ:SCYX), Terns Pharma (NASDAQ:TERN) and Ocuphire Pharma (NASDAQ:OCUP).
The latest price target for Akari Therapeutics (NASDAQ: AKTX) was reported by B. Riley Securities on Friday, March 13, 2020. The analyst firm set a price target for 5.00 expecting AKTX to rise to within 12 months (a possible 403.68% upside). 0 analyst firms have reported ratings in the last year.
The stock price for Akari Therapeutics (NASDAQ: AKTX) is $0.9927 last updated June 24, 2022, 8:00 PM UTC.
There are no upcoming dividends for Akari Therapeutics.
Akari Therapeutics’s Q2 earnings are confirmed for Wednesday, September 21, 2022.
There is no upcoming split for Akari Therapeutics.
Akari Therapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.